These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26634686)

  • 1. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance.
    Barber TM; Dimitriadis GK; Andreou A; Franks S
    Clin Med (Lond); 2015 Dec; 15 Suppl 6():s72-6. PubMed ID: 26634686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance.
    Barber TM; Dimitriadis GK; Andreou A; Franks S
    Clin Med (Lond); 2016 Jun; 16(3):262-6. PubMed ID: 27251917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and polycystic ovary syndrome.
    Barber TM; Franks S
    Clin Endocrinol (Oxf); 2021 Oct; 95(4):531-541. PubMed ID: 33460482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
    Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ
    Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies.
    Barber TM; Hanson P; Weickert MO; Franks S
    Clin Med Insights Reprod Health; 2019; 13():1179558119874042. PubMed ID: 31523137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why are women with polycystic ovary syndrome obese?
    Barber TM
    Br Med Bull; 2022 Sep; 143(1):4-15. PubMed ID: 35284917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of changes in dietary habits in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Reprod Biomed Online; 2004 Apr; 8(4):431-9. PubMed ID: 15149567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of obesity in the development of polycystic ovary syndrome.
    Motta AB
    Curr Pharm Des; 2012; 18(17):2482-91. PubMed ID: 22376149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance.
    Ketel IJ; Stehouwer CD; Serné EH; Korsen TJ; Hompes PG; Smulders YM; de Jongh RT; Homburg R; Lambalk CB
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3365-72. PubMed ID: 18593766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin and the polycystic ovary syndrome.
    Macut D; Bjekić-Macut J; Rahelić D; Doknić M
    Diabetes Res Clin Pract; 2017 Aug; 130():163-170. PubMed ID: 28646699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum metabolomics profiling by proton nuclear magnetic resonance spectrometry of the response to single oral macronutrient challenges in women with polycystic ovary syndrome (PCOS) compared with male and female controls.
    Escobar-Morreale HF; Martínez-García MÁ; Insenser M; Cañellas N; Correig X; Luque-Ramírez M
    Biol Sex Differ; 2023 Sep; 14(1):62. PubMed ID: 37736753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS).
    Shirazi FKH; Khodamoradi Z; Jeddi M
    BMC Endocr Disord; 2021 Mar; 21(1):45. PubMed ID: 33750349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.
    Teede H; Deeks A; Moran L
    BMC Med; 2010 Jun; 8():41. PubMed ID: 20591140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Glintborg D
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
    Sanchez-Garrido MA; Tena-Sempere M
    Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
    Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
    Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.